Profile data is unavailable for this security.
About the company
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
- Revenue in USD (TTM)247.00m
- Net income in USD-249.00m
- Incorporated2015
- Employees577.00
- LocationArcus Biosciences Inc3928 Point Eden WayHAYWARD 94545-3719United StatesUSA
- Phone+1 (510) 694-6200
- Fax+1 (302) 730-1370
- Websitehttps://arcusbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Longboard Pharmaceuticals Inc | 0.00 | -64.74m | 1.32bn | 50.00 | -- | 4.47 | -- | -- | -2.16 | -2.16 | 0.00 | 7.58 | 0.00 | -- | -- | 0.00 | -34.15 | -- | -36.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
Cassava Sciences Inc | 0.00 | -15.37m | 1.43bn | 29.00 | -- | 7.56 | -- | -- | -0.4054 | -0.4054 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -6.97 | -30.74 | -8.35 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
Disc Medicine Inc | 0.00 | -91.00m | 1.43bn | 74.00 | -- | 2.92 | -- | -- | -3.66 | -3.66 | 0.00 | 16.45 | 0.00 | -- | -- | 0.00 | -20.35 | -- | -21.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
ARS Pharmaceuticals Inc | 500.00k | -44.84m | 1.43bn | 23.00 | -- | 6.65 | -- | 2,863.66 | -0.466 | -0.466 | 0.0052 | 2.22 | 0.0021 | -- | -- | 20,833.33 | -18.66 | -20.37 | -19.33 | -21.32 | -- | -- | -8,968.40 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
Ardelyx Inc | 210.00m | -65.15m | 1.44bn | 267.00 | -- | 9.82 | -- | 6.87 | -0.2788 | -0.2788 | 0.9052 | 0.6244 | 0.7572 | 2.74 | 9.06 | 786,513.10 | -23.49 | -46.14 | -30.26 | -57.32 | 86.03 | 88.15 | -31.02 | -240.87 | 3.99 | -6.91 | 0.4055 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
Xencor Inc | 133.62m | -177.37m | 1.47bn | 280.00 | -- | 2.31 | -- | 11.02 | -2.90 | -2.90 | 2.19 | 9.14 | 0.1666 | -- | 6.35 | 477,207.20 | -22.40 | -3.70 | -24.25 | -4.12 | -- | -- | -134.45 | -15.92 | -- | -- | 0.0331 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
Belite Bio Inc (ADR) | 0.00 | -35.29m | 1.48bn | 20.00 | -- | 12.94 | -- | -- | -1.23 | -1.23 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -39.40 | -- | -39.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
Dynavax Technologies Corp | 249.70m | 17.18m | 1.49bn | 408.00 | 112.25 | 2.31 | 68.65 | 5.96 | 0.1011 | 0.1011 | 1.76 | 4.91 | 0.2557 | 0.7766 | 4.76 | 611,997.60 | 1.76 | 4.16 | 1.86 | 5.71 | 82.03 | 64.83 | 6.88 | 9.19 | 13.18 | -- | 0.2578 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
Arcus Biosciences Inc | 247.00m | -249.00m | 1.51bn | 577.00 | -- | 2.37 | -- | 6.10 | -3.10 | -3.10 | 3.02 | 6.96 | 0.2053 | -- | 7.06 | 428,076.30 | -20.70 | -15.85 | -24.57 | -18.25 | -- | -- | -100.81 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
Spyre Therapeutics Inc | 0.00 | -185.98m | 1.53bn | 50.00 | -- | 7.01 | -- | -- | -15.42 | -15.42 | 0.00 | 7.37 | 0.00 | -- | -- | 0.00 | -54.73 | -101.87 | -87.47 | -118.83 | -- | -- | -- | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
Syndax Pharmaceuticals Inc | 3.50m | -264.08m | 1.55bn | 112.00 | -- | 3.58 | -- | 444.20 | -3.38 | -3.38 | 0.0447 | 5.11 | 0.0077 | -- | 0.6132 | 31,250.00 | -58.15 | -27.90 | -63.20 | -30.15 | -- | -- | -7,545.20 | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
CareDx Inc | 297.08m | -159.64m | 1.56bn | 635.00 | -- | 5.89 | -- | 5.26 | -2.99 | -2.99 | 5.62 | 5.03 | 0.6053 | 5.46 | 5.04 | 467,848.80 | -32.53 | -17.54 | -38.52 | -20.85 | 64.98 | 65.50 | -53.73 | -27.78 | 3.85 | -- | 0.00 | -- | -12.89 | 29.63 | -148.37 | -- | 5.01 | -- |
Kura Oncology Inc | 0.00 | -181.75m | 1.61bn | 142.00 | -- | 3.44 | -- | -- | -2.23 | -2.23 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -36.00 | -26.04 | -38.16 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0198 | -- | -- | -- | -12.36 | -- | -- | -- |
Nurix Therapeutics Inc | 62.30m | -165.00m | 1.65bn | 284.00 | -- | 4.45 | -- | 26.49 | -2.92 | -2.92 | 1.10 | 5.76 | 0.1446 | -- | -- | 219,376.80 | -38.30 | -33.01 | -46.57 | -39.66 | -- | -- | -264.84 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
BioCryst Pharmaceuticals Inc | 382.24m | -145.93m | 1.68bn | 536.00 | -- | -- | -- | 4.39 | -0.7301 | -0.7301 | 1.90 | -2.30 | 0.7627 | 0.3747 | 6.05 | 713,126.90 | -29.12 | -47.95 | -37.43 | -64.89 | 98.46 | 97.06 | -38.18 | -114.94 | 2.78 | -0.6999 | 2.30 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 8.65m | 9.51% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.90m | 5.39% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 4.78m | 5.26% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 4.69m | 5.15% |
Woodline Partners LPas of 31 Mar 2024 | 2.88m | 3.17% |
Point72 Asset Management LPas of 31 Mar 2024 | 1.91m | 2.11% |
Dimensional Fund Advisors LPas of 30 Jun 2024 | 1.40m | 1.54% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.23m | 1.36% |
AllianceBernstein LPas of 31 Mar 2024 | 1.15m | 1.27% |
Threadneedle Asset Management Ltd.as of 31 Mar 2024 | 1.04m | 1.14% |